General MedicationsORALGeneric

ABACAVIR SULFATE; LAMIVUDINE

Standard Dose

600MG; 300MG

Max Dose

Refer to approved labeling

Primary Use

Marketing status: None (Tentative Approval)

Summary

Approval overview ABACAVIR SULFATE; LAMIVUDINE is listed in Drugs@FDA under application 090519 (ANDA).

Marketing status: None (Tentative Approval) Active ingredient ABACAVIR SULFATE; LAMIVUDINE Form and strength TABLET; ORAL - 600MG; 300MG Sponsor MATRIX LABS LTD Submission history Latest submission status date: 2009-03-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview ABACAVIR SULFATE; LAMIVUDINE is listed in Drugs@FDA under application 090519 (ANDA). Marketing status: None (Tentative Approval) Active ingredient ABACAVIR SULFATE; LAMIVUDINE Form and strength TABLET; ORAL - 600MG; 300MG Sponsor MATRIX LABS LTD Submission history Latest submission status date: 2009-03-30 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)

Interaction Notes

No interaction notes stored yet.